recent success monoclonal antibody cocktail zmapptm mil ebola virus erov infect reign interest antibodybas therapeutic since product process antibody prolong costly alter treatment investing product purify equip antiserum hours hyperimmun viruslik partial test postexposur efficacy mouse model infect basic mouse given mg per anim minut day postinfect dpi anim survive decrease possible serum sick digest pepsi genre fab fragment vitro neutral active compare whole immunoglobulin full protect achieve treatment init suboptim observe minut group demons admit neutral depend meghan may also contribute survive guinea pig start full protect result justify future studi product hp 